Equities research analysts expect Adaptimmune Therapeutics PLC (NASDAQ:ADAP) to announce $5.43 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Adaptimmune Therapeutics PLC’s earnings. The lowest sales estimate is $3.00 million and the highest is $7.40 million. Adaptimmune Therapeutics PLC posted sales of $2.42 million during the same quarter last year, which suggests a positive year-over-year growth rate of 124.4%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 9th.
On average, analysts expect that Adaptimmune Therapeutics PLC will report full year sales of $5.43 million for the current fiscal year, with estimates ranging from $11.90 million to $25.00 million. For the next financial year, analysts forecast that the business will post sales of $21.19 million per share, with estimates ranging from $12.00 million to $30.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Adaptimmune Therapeutics PLC.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.24). The company had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 41.07%.
Several equities analysts recently weighed in on ADAP shares. BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Saturday, July 8th. Cowen and Company reiterated a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $12.08.
A number of large investors have recently added to or reduced their stakes in the company. AXA bought a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at approximately $4,959,000. Renaissance Technologies LLC raised its stake in Adaptimmune Therapeutics PLC by 35.4% in the fourth quarter. Renaissance Technologies LLC now owns 445,100 shares of the biotechnology company’s stock valued at $1,803,000 after buying an additional 116,400 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at approximately $2,883,000. Raymond James Financial Services Advisors Inc. bought a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at approximately $120,000. Finally, Creative Planning raised its stake in Adaptimmune Therapeutics PLC by 32.8% in the first quarter. Creative Planning now owns 40,500 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 10,000 shares in the last quarter. Institutional investors and hedge funds own 56.16% of the company’s stock.
Adaptimmune Therapeutics PLC (NASDAQ ADAP) opened at 5.43 on Friday. The stock’s market capitalization is $507.68 million. Adaptimmune Therapeutics PLC has a 12-month low of $3.76 and a 12-month high of $8.89.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.
